Zentalis Pharmaceuticals, Inc., is a medium-risk pharmaceutical company based in the United States that specializes in developing small molecule therapeutics for cancer treatment. With a strong focus on ESG principles, Zentalis Pharmaceuticals uses an Integrated Discovery Engine to identify targets and develop potentially differentiated product profiles. The company's pipeline includes two lead product candidates, ZN-c5 for advanced breast cancer and ZN-c3 for solid tumors and ovarian cancer.